Current understanding in the management of sickle cell disease
- PMID: 20001613
- DOI: 10.3109/03630260903347682
Current understanding in the management of sickle cell disease
Abstract
Sickle cell disease (SCD), the commonest monogenetic disorder worldwide, represents a major public health burden because of its significant morbidity and mortality. Advances in molecular and cellular biology have resulted in an accumulation of knowledge on sickle cell pathophysiology and broadened our understanding of the complexity of this molecular disease with heterogeneous manifestations. Natural history studies and clinical trials have provided incremental data on clinical features, complications, and predictors of severity in SCD and, above all, have laid important recommendations for prevention and treatment of complications. Disease modifying therapies that have significantly improved survival of SCD patients have been identified over recent years. Despite increasingly successful therapies and better overall survival, patients continue to die especially with increasing age and health providers caring for SCD patients face major challenges. This article will highlight modern management of SCD and its impact on the lives of affected patients.
Similar articles
-
Current issues in blood transfusion for sickle cell disease.Curr Opin Pediatr. 2009 Feb;21(1):15-21. doi: 10.1097/MOP.0b013e328321882e. Curr Opin Pediatr. 2009. PMID: 19242238 Review.
-
Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines.Transfus Med Rev. 2007 Apr;21(2):118-33. doi: 10.1016/j.tmrv.2006.11.003. Transfus Med Rev. 2007. PMID: 17397762 Review.
-
Three decades of innovation in the management of sickle cell disease: the road to understanding the sickle cell disease clinical phenotype.Blood Rev. 2005 Mar;19(2):99-110. doi: 10.1016/j.blre.2004.04.002. Blood Rev. 2005. PMID: 15603913 Review.
-
A primary care provider's guide to preventive and acute care management of adults and children with sickle cell disease.J Am Acad Nurse Pract. 2009 May;21(5):250-7. doi: 10.1111/j.1745-7599.2009.00401.x. J Am Acad Nurse Pract. 2009. PMID: 19432908 Review.
-
Sickle cell disease in pregnancy. Obstetric and anesthetic management perspectives.Saudi Med J. 2004 Mar;25(3):265-76. Saudi Med J. 2004. PMID: 15048161 Review.
Cited by
-
What is behind a relapse of thrombotic thrombocytopenic purpura?Intern Emerg Med. 2018 Aug;13(5):709-712. doi: 10.1007/s11739-017-1764-z. Epub 2017 Nov 2. Intern Emerg Med. 2018. PMID: 29094300 No abstract available.
-
Oral Monomethyl Fumarate Therapy Ameliorates Retinopathy in a Humanized Mouse Model of Sickle Cell Disease.Antioxid Redox Signal. 2016 Dec 10;25(17):921-935. doi: 10.1089/ars.2016.6638. Epub 2016 Aug 22. Antioxid Redox Signal. 2016. PMID: 27393735 Free PMC article.
-
Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.Cochrane Database Syst Rev. 2015 Dec 18;2015(12):CD010155. doi: 10.1002/14651858.CD010155.pub3. Cochrane Database Syst Rev. 2015. PMID: 26684281 Free PMC article.
-
A retrospective analysis of the cost of hospitalizations for sickle cell disease with crisis in England, 2010/11.J Public Health (Oxf). 2015 Sep;37(3):529-39. doi: 10.1093/pubmed/fdu026. Epub 2014 May 5. J Public Health (Oxf). 2015. PMID: 24796312 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical